Bassel F. El-Rayes, MD, Appointed Deputy Director of Moores Cancer Center
|
Dr. Bassel F. El-Rayes will begin his tenure as Moores Deputy Director, effective February 1, 2026. A leader in gastrointestinal cancer research and clinical care, Dr. El-Rayes will help advance programs and expand access to innovative therapies at Moores.
Learn More»
|
GLP-1 Drugs Linked to Dramatically Lower Death Rates in Colon Cancer Patients
|
|
|
Moores Member Raphael Cuomo, PhD has found that GLP-1 drugs, such as Ozempic, may improve outcomes in colon cancer outcomes. Learn More»
|
Precision Therapy Could Stop Triple-Negative Breast Cancer (TNBC) at the Source |
UC San Diego researchers have developed an antibody-drug conjugate that targets TNBC tumor-initiating cells that reduces tumor growth in preclinical models, which could provide a new therapy for this aggressive cancer. Learn More»
|
|
|
Keep Abreast of Funding Opportunities
|
|
|
2025 MOORES ANNUAL SCIENTIFIC RETREAT SYNOPSIS
|
The 2025 Moores Scientific Retreat convened over 300 faculty, staff, trainees, and collaborators for a day of scientific exchange on the La Jolla shore. Presentations showcased the advanced research in basic, translational, clinical, and population science occuring at Moores, which features innovations from immune networks and RNA-binding proteins to AI-driven cancer discoveries and advances in prevention and imaging.
Retreat awards recognized not only the top trainee posters from each of the five Moores Research Programs, but also Moores Members who have earned their first NIH R01 grant or launched their first clinical trial—both major career milestones in science. This year’s retreat reiterates Moores’ commitment to collaboration and innovation in advancing cancer care throughout the catchment area and beyond.
Read the full story here | View full photo gallery
Watch retreat videos below!
|
|
|
Gerontology Research Collaborative and Stein Institute for Research on Aging In This Day & Age Seminar Series |
Date: Thursday, November 20, 2025
Time: 4:00 p.m. to 5:00 p.m.
Place: UCSD Medical Education and Telemedicine Building, Room 223 and Zoom
|
In this presentation for researchers, students, and anyone interested in advances in aging science, Sanju Sinha, PhD will highlight research on aging that addresses data science, cancer metabolism, and the aging process itself.
Learn More»
|
|
|
Sanford Integrated Space Stem Cell Orbital Research Center Town Hall |
Date: Thursday, November 20, 2025
Time: 11:30 a.m. to 12:30 p.m.
Place: Duane Roth Auditorium
|
This event will showcase how the space environment is transforming translational research and accelerating discoveries on Earth. Presentations will address new tools for space-based research, space medicine, education, and the growing space economy. Register Now»
|
|
|
FEATURED FUNDING OPPORTUNITIES |
View featured limited submission, federal, and non-federal grant and funding opportunities. |
ACTRI K12 Mentored Career Development Award
|
Equivalent to an NIH K23, K01, or K08, this award provides up to 3 years of support for early-career faculty members with $115,000/year toward salary, plus benefits, and $10,000/year in research and travel funds.
|
Application Deadline: November 21, 2025, 11:59 p.m. PST
Apply Now»
|
|
|
|
A meta-analysis of experimentally validated neo-epitopes: Patterns, biases, and opportunities |
Cancer Immunology, Immunotherapy
|
Alessandro Sette, PhD (Hematologic Malignancies), Hannah Carter, PhD, MEng, (Structural and Functional Genomics), Stephen Schoenberger, PhD (Solid Tumor Therapeutics), and Bjoern Peters, PhD (Structural and Functional Genomics)
|
|
|
|
Targeting FSP1 triggers ferroptosis in lung cancer
|
Diane Simeone, MD (Cancer Biology and Signaling)
|
|
| | CD40 transcriptomic expression patterns across malignancies: Implications for clinical trials of CD40 agonists
|
Cancer Immunology, Immunotherapy
|
Jason Sicklick, MD (Structural and Functional Genomics) and Shumei Kato, MD (Structural and Functional Genomics)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
|
|
CCTL019A2205B: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
PI: Ayad Hamdan, MD
NCT ID: NCT02445222
|
|
|
|